DOCSLIB.ORG

Linetsky Irina Curriculum Vitae

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Linetsky Irina Curriculum Vitae Linetsky Irina 01/01/19 Curriculum Vitae 1.Personal details Name: Linetsky Irina I.D:306342858 Date of birth: 18.05.1977 Country birth: Ukraine . Date of immigration: 30.10.1990 Home address: str.Levitas 28/1, Hadera, Israel. Tel: 050-4905205 Electronic Address: [email protected] 2.Higher Education Period of study Name of Degree Year of Institution and Approval of Department Degree 1996-1999 "Pat Matthews" Registered nurse 1999 Academic School diploma (R.N) of Nursing, Hillel Yaffe Medical Center 1991-2001 The Department Bachelor Degree 2002 of Nursing, in nursing (B.A) Sackler Faculty of Medicine, Tel Aviv University. 2006-2008 School of Public M.H.A in Health 2009 Health, Faculty of System Social Welfar & Management Health Sciences,Univesity of Haifa. 3.Professional training Dates Name of Institution Diploma/course 2000 "Pat Matthews" Managerial enrichment Academic School of course Nursing, Hillel Yaffe Medical Center. 2002 "Pat Matthews" Breast feeding Academic School of counseling course Nursing, Hillel Yaffe Medical Center. 2002-2003 Advanced Practice- -Midwife license Nursing program in - Nurse-Midwifery, Childbirth Education Rambam Health Course teaching Care Campus license 2004 Nursing school, Diabetes mellitus course Laniado Hospital For the role of "Diabetic Trustee" 2010 "Pat Matthews" Clinical Training course Academic School of Clinical Instructor Nursing , Hillel Yaffe Diploma. Medical Center. 2014 "Pat Matthews" GCP (Good Clinical Academic School of Practice) course Nursing , Hillel Yaffe Medical Center. 2018 MSR - Israel Center Workshop for writing for Medical scenarios for medical Simulation simulation 2019 MSR - Israel Center Medical Simulation for Medical Instructor Training Simulation Course 4.Employment Dates Name of Ranks/ Position Institution and Depsrtment 1998-1999 "Atidim Medigroup" Nurse in recovery Medical Center ward 2001-2005 Laniado Hospital, -Nurse in High risk Netanya department -Delivery room midwife -Diabetic Trustee role 1999-current Hillel Yaffe Medical -Senior Midwife Center, Delivery Room - Shift supervisor -Clinical guide for nursing students, gynecology residents, new midwifes and nurses in Midwifery program. -Manager of Delivery Ward Forum. 2013-current Ruppin Academic Lecturer in the Center Nursing Department and simulation center 2014-current Israel Center for examiner in MSR Medical Simulation, Tel Hashomer Hospital 2017 Advanced Practice- Lecturer in Midwife Nursing program in Advanced Practice Nurse-Midwifery, Program Rambam Health Care Campus 2018 Hillel Yaffe Medical Clinical Training Center, Delivery Room Coordinator 5.Professional Seminar Date Name of Place of Subject of Role Seminar Seminar Lecture 2014 Seminar for Hillel Yaffe "Vaginismus: -Active role nurses and Medical coping during in arranging midwifes Center the delivery a seminar about by the -Personal "Innovations woman and lecture topic in delivery room midwifery". team." 2006- Hillel Yaffe Workshop instructor current Medical instructor in Center obstetric topics for maternity ward nurses, high risk department nurses and midwifes 6.Prizes Dean's prize for excellent lecturer for 2015,2016 7.Teaching experience Year Name of Type of Degree Number of Course Course/Lecture Students 2001 School for Anatomy Lecturer 20 medical course secretaries 2004 Diabetes Gestational Lecturer 40 Mellitus Diabetes trustee course course, Laniado Hospital 2000- Delivery Clinical guide Clinical Personal current room, Hillel for nursing guide Yaffe and medical Medical students, center. gynecology residents, new midwifes and nurses in Midwifery program 2013- Nursing Lecturer in Lecturer 60 current Department, the Ruppin gynecology Academic and obstetrics Center course and a simulation lab guide 2017 Midwife Midwifery Lecturer 40 Advanced Practice Program 8.Added qualifications: -2009-current Manager of Delivery Ward Forum, Hillel Yaffe Hospital. -Involvement in writing delivery ward department medical guidelines, Hillel Yaffe Hospital. For example: Diabetes mellitus guidelines, management of the 3'rd stage of delivery guidelines. .
Load more

Recommended publications
  • Spotted Fever Group Rickettsioses in Israel, 2010–2019
    Spotted Fever Group Rickettsioses in Israel, 2010–2019 Regev Cohen, Talya Finn, Frida Babushkin, Yael Paran, Ronen Ben Ami, Alaa Atamna, Sharon Reisfeld, Gabriel Weber, Neta Petersiel, Hiba Zayyad, Eyal Leshem, Miriam Weinberger, Yasmin Maor, Nicola Makhoul, Lior Nesher, Galia Zaide, Dar Klein, Adi Beth-Din, Yafi t Atiya-Nasagi ≈ In a multicenter, nationwide, retrospective study of pa- SFGRs are associated with 20 species of Rickettsia, tients hospitalized with spotted fever group rickettsiosis of which 16 are considered human pathogens (1,2). in Israel during 2010–2019, we identifi ed 42 cases, of Recent introduction of molecular methods provided which 36 were autochthonous. The most prevalent spe- more information about SFGR agents causing human cies was the Rickettsia conorii Israeli tick typhus strain (n disease and enabled their identifi cation, for which = 33, 79%); infection with this species necessitated inten- the clinical signifi cance of some remains lacking (3). sive care for 52% of patients and was associated with a R. conorii complex, the etiologic agent of Mediterra- 30% fatality rate. A history of tick bite was rare, found for nean spotted fever, includes 4 strains: R. conorii Mal- only 5% of patients; eschar was found in 12%; and leuko- ish (cause of Mediterranean spotted fever), R. conorii cytosis was more common than leukopenia. Most (72%) Astrakhan (cause of Astrakhan fever), R. conorii In- patients resided along the Mediterranean shoreline. For 3 dian tick typhus (cause of Indian tick typhus), and R. patients, a new Rickettsia variant was identifi ed and had been acquired in eastern, mountainous parts of Israel.
    [Show full text]
  • State of the //ART// of the State
    State of the //ART// of the State A Political Economy of Assisted Reproduction in Palestine/Israel Sigrid Vertommen Dissertation submitted in fulfillment of the requirements for the degree of Doctor in Political and Social Sciences, option Political Sciences. Middle East and North Africa Research Group - Department of Conflict and Development Studies, Ghent University March 2017 Supervisor: Prof. dr. Sami Zemni Cover design by Aïlien Reyns TABLE OF CONTENTS Summary ................................................................................................................................................................................ v Samenvatting ..................................................................................................................................................................... vi List of Abbreviations ...................................................................................................................................................... vii List of Figures .................................................................................................................................................................... ix Acknowledgements ......................................................................................................................................................... xi Introduction ....................................................................................................................................................... 1 State of the ART ............................................................................................................................................................
    [Show full text]
  • Scientific Program
    The 63th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery April 12-13 • 2016 • Tel Aviv, Israel SCIENTIFIC PROGRAM Paragon Israel (Dan Knassim) Paragon Tel/Fax:03-5767730/7 Israel (Dan Knassim) a Paragon Group Company [email protected] TUESDAY, APRIL 12, 2016 08:30-10:00 Interventional Cardiology I Hall A Chairs: Ariel Finkelstein, Ran Kornowski, Israel 08:30 Effect of Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes: a propensity score-matched analysis Amos Levi1,2, Tamir Bental1,2, Hana Veknin Assa1,2, Gabriel Greenberg1,2, Eli Lev1,2, Ran Kornowski1,2, Abid Assali1,2 1Cardiology, Rabin Medical Center, Israel 2Sackler Faculty of Medicine, Tel Aviv University, Israel 08:41 Percutaneous Valve-in-Valve Implantation for the Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Degeneration Uri Landes1, Abid Assali1, Ram Sharoni1,2, Hanna Vaknin-Assa1, Katia Orvin1, Amos Levi1, Yaron Shapira1, Shmuel Schwartzenberg1, Ashraf Hamdan1, Tamir Bental1, Alexander Sagie1, Ran Kornowski1 1Department of Cardiology, Rabin Medical Center, Tel Aviv, Israel 2Department of Cardiac Surgery, Rabin Medical Center, Tel Aviv, Israel 08:52 Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome Uri Landes1, Alon Barsheshet1, Abid Assali1, Hanna Vaknin-Assa1, Israel Barbash3, Victor Guetta3, Amit Segev3, Ariel Finkelstein2, Amir Halkin2, Jeremy Ben-Shoshan2,
    [Show full text]
  • Antibiotic Treatment for Invasive Listeriosis and Patient
    Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PeterPen) ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-040210 Article Type: Protocol Date Submitted
    [Show full text]
  • P2463 Antibiotic Treatment for Invasive Listeriosis and Patient
    P2463 Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein*1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav5,3, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami9,3, Miriam Weinberger10,3, Galia Rahav11,3, Yasmin Maor12,3, Michal Chowers13,3, Ran Nir-Paz2, Mical Paul8,14 1 Rambam Healthcare Campus, Haifa, Israel, 2 Hadassah University Hospital - Ein Kerem, Jerusalem, Israel, 3 Tel Aviv University, Sackler Faculty of Medicine, Ramat Aviv, Israel, 4 Soroka Medical Center, Beersheba, Israel, 5 Rabin Medical Center, Petah Tikva, Israel, 6 Shaare Zedek, Jerusalem, Israel, 7 Laniado Hospital, Netanya, Israel, 8 Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, 9 Tel Aviv Sourasky Medical Center , Tel Aviv, Israel, 10 Assaf Harofeh Medical Center, Be’er Ya’akov, Israel, 11 Sheba Medical Center, Ramat Gan, Israel, 12 Wolfson Medical Center, Holon, Israel, 13 Meir Medical Center, Kefar Sava, Israel, 14 Infectious Diseases Unit, Rambam Health Care Campus, Haifa, Israel Background: Current recommendations for treatment of invasive listeriosis suggest ampicillin-based therapy with the addition of an aminoglycoside. However, several reports have suggested higher morbidity and mortality with this regimen as compared with beta-lactam monotherapy. We aimed to evaluate the association between penicillin-aminoglycoside combination therapy and mortality in patients with invasive listeriosis while adjusting for timing of treatment onset. Materials/methods: This is a multicenter retrospective observational study of adult patients with invasive listeriosis (primary bacteremia, central nervous system [CNS] disease and pregnancy-associated listeriosis) in 11 hospitals in Israel between the years 2008-2014. We evaluated the effect of penicillin-based monotherapy compared with early combination therapy with gentamicin, defined as treatment started within 48 hours of culture results and continued for a minimum duration of 7 days.
    [Show full text]
  • General Hospital Beds in Israel
    Overview Date: 13 Kislev 5780, 11 December 2019 Written by: Aharon Blank, Flora Koch Davidovich | Approved by: Shelly Levy, Team Leader General hospital beds in Israel There are 45 general hospitals in Israel, a quarter of which are government-owned (nine government hospitals and two government–municipal hospitals).1 A general hospital is comprised of the following wards: internal medicine, intensive care, pediatrics, surgery, maternity wards, and intermediate care wards. Israel has a shortage of beds in general hospitals; for many years, various parties—including the State Comptroller—have noted the gap between the demands made of the system of general hospitals and the resources allocated to it, and they have called for long-term planning of the system of general hospitals in Israel.2 According to data from the Ministry of Health, in January 2019 there were 16,021 acute care beds in Israel—15,871 in general hospitals and 151 in geriatric hospitals. The rate of acute care beds in Israel has been declining since the late 1970s; as of 2019, it stands at 1.78 beds per 1,000 people, as compared to 1.88 in 2011 and 2.09 in 2005.3 Ministry of Health data from January 2019 on the geographic distribution of acute care beds indicates that nearly half are located in the central district (23.8%) and Tel Aviv (21.4%), while the remaining beds are in the Haifa district (15.2%), Jerusalem (14.5%), the northern district (12.7%) and the southern district (12.3%).4 A comparison of the rate of acute care beds in hospitals per 1,000 people in Israel to the rate in 34 OECD member states, based on data from 2017,5 indicates a decline in the rate of acute care beds in hospitals in OECD countries due to technological developments and the expansion of community healthcare services, among other things.
    [Show full text]
  • 15 July, 2021 to the Honourable: Prime Minister Naftali
    15 July, 2021 To the Honourable: Prime Minister Naftali Bennett Re: Severe Warning – A Lockdown During The Upcoming Holidays Will be Catastrophic Urgent Request for a Meeting with the Prime Minister To the Honourable Prime Minister, Firstly, we wish to congratulate you on the formation of the new government. The complexity of the task you have taken on is unparalleled, certainly in these challenging times, and we wish you heartfelt success. We are hearing warnings of an impending lockdown during the upcoming holiday period, and we would like to state clearly and strongly - another lockdown will be nothing short of a catastrophe. The Public Emergency Council is a spontaneous initiative of doctors and researchers who felt that it was no longer possible to remain silent in the face of the outgoing government's steps to contain the COVID- 19 pandemic. As you can see below, among the members of the Council are individuals who constituted and still constitute the backbone of the medical establishment in this country, individuals who are at the heart of the medical consensus: four Israel Prize laureates, a Nobel laureate, experts who have managed four hospitals, a former Director General of the Ministry of Health, a HMO Director General, an IDF Deputy Chief Medical Officer, a founding member of Israel’s epidemic treatment team and an expert in disaster situations, university department heads, deans and deputy deans of medical faculties, all of whom have joined together in an extraordinary step, without any political, commercial or personal interest, in order to contribute the vast knowledge and experience which they have acquired to the relevant decision makers.
    [Show full text]
  • 1 CURRICULUM VITAE Anat E. Leibler June, 2014 1. PERSONAL DETAILS Address: 7 Moshe Sneh Street, Ra'anana 43728 ISRAEL Telep
    Anat E. Leibler June 2014 CURRICULUM VITAE Anat E. Leibler June, 2014 1. PERSONAL DETAILS Address: 7 Moshe Sneh Street, Ra’anana 43728 ISRAEL Telephone: 0544-207067 E-mail: [email protected] 2. HIGHER EDUCATION 1988 B.Ed, Beit Berl College, Kfar Sava, Israel 1998 MA, (Magna Cum Laude) Tel Aviv University, Department of Sociology and Anthropology Thesis: Statistics as Social Architecture: On the Construction of the Central Bureau of Statistics as an A-political Institution (Hebrew) Advisors: Daniel Breslau, Tel Aviv University, and Michael Shalev, the Hebrew University of Jerusalem 1999-2000 Doctoral studies at Tel Aviv University. 2000-2004 PhD student, University of California at San Diego, Department of Sociology and the Science Studies Program 2004 PhD Candidate, University of California at San Diego, Department of Sociology and the Science Studies Program 2008 PhD, UCSD, in Science Studies and Sociology, University of California, San Diego. December. Co-Chairs: Theodore Porter, (UCLA) and Nancy Cartwright, (UCSD and LSE). Committee Members: Chandra Mukerji, Andrew Lakoff, Richard Biernacki and Steve Epstein (UCSD) 2007-2008 Postdoctoral Fellow, Department of Political Science, Hebrew University of Jerusalem, Israel. (See #7, #13). 2011-2012 Post-Doctoral Fellow, Edelstein Center for the History and Philosophy of Science, Technology and Medicine. (See #2). 3. ACADEMIC APPOINTMENTS 2008- Teaching Fellow, Science, Technology and Society Studies Program, Bar-Ilan University. 2008-2009 Teaching Fellow, History, Philosophy and Sociology of Science Program, The Hebrew University of Jerusalem. 2012 -2013 Teaching Fellow, History Department, The Hebrew University of Jerusalem. 1 Anat E. Leibler June 2014 2013- Teaching Fellow, The Department of Politics and Government, Ben- Gurion University.
    [Show full text]
  • Research Article the Effect of Medical Cannabis on Pain Level and Quality of Sleep Among Rheumatology Clinic Outpatients
    Hindawi Pain Research and Management Volume 2021, Article ID 1756588, 6 pages https://doi.org/10.1155/2021/1756588 Research Article The Effect of Medical Cannabis on Pain Level and Quality of Sleep among Rheumatology Clinic Outpatients George Habib ,1,2,3 Fadi Khazin ,4 and Suheil Artul 3,5 1Rheumatology Unit, Laniado Hospital, Netanya, Israel 2Rheumatology Clinic, Nazareth Hospital, Nazareth, Israel 3Faculty of Medicine, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel 4Orthopedic Department, Lady Davis Medical Center, Haifa, Israel 5Department of Radiology, Nazareth Hospital, Nazareth, Israel Correspondence should be addressed to George Habib; [email protected] Received 15 April 2021; Revised 14 August 2021; Accepted 18 August 2021; Published 7 September 2021 Academic Editor: Anna Maria Aloisi Copyright © 2021 George Habib et al. &is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Introduction. Medical cannabis (MC) is becoming increasingly popular for the treatment of chronic pain conditions. In this study, we evaluated the effect of MC treatment on pain level and quality of sleep of patients with different medical conditions at the rheumatology clinic. Methods. Patients licensed for the use of MC at the rheumatology clinics at different settings were located and contacted. &eir demographic and clinical parameters were documented, including type of medical cannabis consumed, way of consumption, and current monthly consumed amount. &ese patients were contacted by phone and asked about the effect on pain level and quality of sleep. Results. A total of 351 patients were located, and 319 completed the questionnaire.
    [Show full text]
  • An International Randomized Controlled Trial (With Videos)
    Accepted Manuscript G-EYE colonoscopy is superior to standard colonoscopy for increasing adenoma detection rate: an international randomized controlled trial (with videos) Haim Shirin, Acquisition of data, critical revision of the manuscript for important intellectual content, Beni Shpak, Acquisition of data, Julia Epshtein, Acquisition of data, John Gásdal Karstensen, Acquisition of data, administrative support, Arthur Hoffman, Acquisition of data, Rogier de Ridder, Acquisition of data, Pier Alberto Testoni, Acquisition of data, Sauid Ishaq, Acquisition of data, D. Nageshwar Reddy, Acquisition of data, Seth A. Gross, Study concept and design , acquisition of data, critical revision of the manuscript for important intellectual content, Helmut Neumann, Acquisition of data, Martin Goetz, Acquisition of data, Dov Abramowich, Acquisition of data, Menachem Moshkowitz, Acquisition of data, Meir Mizrahi, Acquisition of data, Peter Vilmann, Acquisition of data, critical revision of the manuscript for important intellectual content, Johannes Wilhelm Rey, Acquisition of data, Silvia Sanduleanu- Dascalescu, Acquisition of data, Edi Viale, Acquisition of data, Hrushikesh Chaudhari, Acquisition of data, Mark B. Pochapin, Study concept and design, Michael Yair, Acquisition of data, Mati Shnell, Acquisition of data, Shaul Yaari, Acquisition of data, Jakob Westergren Hendel, Acquisition of data, Daniel Teubner, Administrative support, Roel M.M. Bogie, Administrative support, Chiara Notaristefano, Acquisition of data, Roman Simantov, Acquisition of data,
    [Show full text]
  • Second Ethics Committee Approval Granted by Leading Israeli Hospital for the Phase II Clinical Trial on COVID-19 Patients
    28 April 2020 Second Ethics Committee Approval Granted by Leading Israeli ASX Code: MXC Hospital for the Phase II Clinical Trial on COVID-19 Patients MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC’ or ‘the Company’), a European based ‘Seed to Medicine’ bio- pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce it has been granted a second Human Research Ethics Committee (‘Ethics Committee’) approval from the Hillel Yaffe Hospital in Israel for an additional site to conduct the Phase II placebo controlled clinical trial to evaluate the safety and efficacy of a natural anti-infective based formulation (‘ArtemiC’ or the ‘Product’) on patients diagnosed with COVID-19 (the ‘Trial’). This is a key milestone for the Company and the planned clinical trial on the Product on patients diagnosed with COVID-19, with the validation from a second leading medical hospital in Israel to run the Phase II trial. Hillel Yaffe Hospital is one of the major specialist hospitals in Israel operating since 1957, specialising in organ implants, trauma and general treatments, having served over 450,000 people. Highlights • ArtemiC is designed with the scientific aim to target viral infections with inflammatory complications, and is now to be evaluated on novel coronavirus 2019 (SARS-CoV-2) infected patients in a double-blind placebo controlled, Phase II clinical trial • MGC has received a second Ethics Committee approval from Hillel Yaffe Hospital in Israel, for the Phase II clinical trial to be undertaken
    [Show full text]